Pomalidomide 4mg Capsules (Pomalid)

Pomalidomide 4mg capsule is classified under the category of medications known as immunomodulatory agents.

For optimal results, it is advisable to take pomalidomide 4mg capsules once daily, with or without food, consistently at the same time each day.

No, the use of pomalidomide 4mg capsules is not advisable for children under the age of 18.

Blood donations are limited while taking Pomalidomide 4mg capsules and for one month after discontinuing the medication. This precaution is in place to avoid the possibility of the donated blood being administered to pregnant women, as the fetuses should not be exposed to this medication.

Patients with a history of blood clots, heart attack, heart failure, breathing difficulty, high blood pressure and cholesterol levels, neuropathy, or hepatitis B virus infection should avoid using Pomalidomide 4mg capsules.

No, it is not advisable to share Pomalidomide 4mg capsules medication with others, even if they exhibit similar symptoms. Doing so may lead to birth defects and other complications.

If you forget to take your scheduled Pomalidomide 4mg capsules dose and it has been less than 12 hours since your usual time, take the missed dose as soon as you remember. However, if more than 12 hours have passed, it is advisable to skip the missed dose. Avoid taking two doses simultaneously.

Patients with a hepatitis B virus infection should not use Pomalidomide 4mg capsules. The treatment with Pomide 2mg capsule may lead to the reactivation of the hepatitis B virus in individuals who have the virus, potentially causing a recurrence of the infection.

Pomalidomide mechanism of action

Pomalidomide directly inhibits angiogenesis and myeloma cell growth. Strong TNF inhibitors like rolipram and pentoxifylline do not stop myeloma cell growth or angiogenesis. Instead, this dual effect is what makes it work in myeloma, not other pathways like TNF alpha inhibition.

Pomalidomide vs Lenalidomide​

Pomalidomide and lenalidomide are both immunomodulatory drugs (IMiDs) used to treat multiple myeloma (MM), but they have different uses and pharmacological profiles.

1. Lenalidomide
People commonly use a generic drug to treat newly diagnosed MM and as maintenance therapy following a stem cell transplant or disease relapse.

2. Pomalidomide
When a patient is not tolerating lenalidomide or when the disease has relapsed or become refractory, doctors use a second-generation IMiD. Patients who have received at least two prior treatments for MM also receive pomalidomide in combination with other drugs.

Here are some other differences between pomalidomide and lenalidomide:

1. Pharmacological profile
Pomalidomide alters the activation of genes and the rate of substrate breakdown, making it more effective against CRBN than lenalidomide.

2. Clinical trials
Clinical trials have shown that pomalidomide can maintain antitumor activity after lenalidomide treatment.

3. Safety profile
Each IMiD has a different safety profile, so it's important to consider this before starting therapy.

4. Toxicity
Pomalidomide is minimally toxic and well tolerated, which is important for patients who have already received multiple treatments.